Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report issued on Monday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Stock Up 2.9 %

RKDA opened at $2.81 on Monday. Arcadia Biosciences has a 52-week low of $1.85 and a 52-week high of $3.93. The company has a 50 day moving average of $2.81 and a two-hundred day moving average of $2.71. The company has a market cap of $3.82 million, a P/E ratio of -0.56 and a beta of 1.34.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. During the same period last year, the company posted ($2.64) earnings per share. Research analysts anticipate that Arcadia Biosciences will post -1.7 earnings per share for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.